The European Commission Directorate-General for Health and Consumers issued three revisions last week that impact various aspects of drug quality and biologic active pharmaceutical ingredients. The modifications range from relatively minor such as changes in one word to more noteworthy changes that involve manufacturing contracts. To learn more about the changes, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.